About NAMS

Founded: n/a
Employees: 100
CEO: Michael Davidson
WebsiteView website: www.newamsterdampharma.com

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Recent NAMS News & Updates

Live News • May 08

NewAmsterdam Pharma Eyes Key 2026 Obicetrapib Milestones and Potential European Launches

NewAmsterdam Pharma reported a Q1 2026 net loss of $48.4 million while continuing to fund development of its lead drug candidate, obicetrapib. Phase 3 trials PREVAIL, REMBRANDT and RUBENS are progressing, with an interim analysis of the PREVAIL cardiovascular outcomes trial planned for Q4 2026 and topline RUBENS data expected by the end of 2026. Regulatory decisions for obicetrapib monotherapy and a fixed-dose combination with ezetimibe are expected in the second half of 2026 in Europe, the UK and Switzerland, with potential product launches by Menarini in Germany and the UK in Q4 2026. For investors, the update ties the current cash burn directly to late-stage clinical and regulatory milestones. The net loss highlights that NewAmsterdam is still in a development-heavy phase, while the PREVAIL, REMBRANDT and RUBENS timelines provide more clarity on when key efficacy and safety data could emerge for obicetrapib in LDL-C lowering and broader cardiometabolic use. The expected regulatory decisions in multiple European markets and potential Menarini launches in Q4 2026 indicate a possible transition from a pure R&D focus to initial commercialization, if approvals are granted. The reported positive pooled data from the BROADWAY and BROOKLYN trials, including kidney function findings, adds clinical context that some investors may consider when evaluating risk around the upcoming Phase 3 readouts and regulatory events.

Recent updates

No updates

NewAmsterdam Pharma Company N.V. Stock Price

NAMS Share Price Performance

NAMS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

NewAmsterdam Pharma Company N.V. Key Details

About NAMS

Recent NAMS News & Updates

Forecast to breakeven in 2028

Industry Analysts Just Made A Substantial Upgrade To Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Forecasts

NewAmsterdam Pharma Eyes Key 2026 Obicetrapib Milestones and Potential European Launches

Recent updates

NewAmsterdam Pharma Company N.V. Competitors

United Therapeutics

BioNTech

Insmed

West Pharmaceutical Services